NCT01356914View on ClinicalTrials.gov

Pacemaker Holter Assessment of the Effect of BMS-914392 on Atrial Fibrillation Burden

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Atrial Fibrillation
Interventions
DRUG

BMS-914392

Tablets, Oral, 10 mg, Every Day (QD), 20 days

DRUG

BMS-914392

Tablets, Oral, 10 mg, Three Times Daily (TID), 20 days

DRUG

BMS-914392

Tablets, Oral, 20 mg, Three Times Daily (TID), 20 days

DRUG

Placebo

Tablets, Oral, 0 mg, Three Times Daily (TID), 20 days

Trial Locations (1)

BN21 2UD

Eastbourne General Hospital, Eastbourne

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT01356914 - Pacemaker Holter Assessment of the Effect of BMS-914392 on Atrial Fibrillation Burden | Biotech Hunter | Biotech Hunter